Menu Search
Equities

Probi AB

PROB:STO

Probi AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)350.00
  • Today's Change-1.00 / -0.28%
  • Shares traded41.22k
  • 1 Year change+71.57%
  • Beta0.5126
Data delayed at least 15 minutes, as of Nov 22 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast in SEK

The one analyst offering a 12 month price target expects Probi AB share price to fall to 210.00 in the next year from the last price of 350.00.
High-40.0%210.00
Med-40.0%210.00
Low-40.0%210.00

Dividends

In 2023, Probi AB reported a dividend of 1.30 SEK, equaling last years dividend. The analyst covering the company expects dividends of 1.50 SEK for the upcoming fiscal year, an increase of 15.38%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in SEK

Probi AB reported annual 2023 earnings of 1.48 per share on Jan 26, 2024.
Average growth rate-28.00%
More ▼

Revenue history & estimates in SEK

of 156.12m. This bettered the 156.00m estimate of the one analyst covering the company.
Average growth rate+2.90%
Probi AB (publ) had revenues for the full year 2023 of 627.69m. This was 1.52% above the prior year's results.
Average growth rate+0.44%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.